424 related articles for article (PubMed ID: 15529257)
1. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
Harcourt JL; Karron RA; Tripp RA
J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
[TBL] [Abstract][Full Text] [Related]
2. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.
Zhang W; Choi Y; Haynes LM; Harcourt JL; Anderson LJ; Jones LP; Tripp RA
J Virol; 2010 Jan; 84(2):1148-57. PubMed ID: 19864390
[TBL] [Abstract][Full Text] [Related]
3. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
Boyoglu-Barnum S; Todd SO; Meng J; Barnum TR; Chirkova T; Haynes LM; Jadhao SJ; Tripp RA; Oomens AG; Moore ML; Anderson LJ
J Virol; 2017 May; 91(10):. PubMed ID: 28275196
[TBL] [Abstract][Full Text] [Related]
4. Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies.
Bergeron HC; Murray J; Nuñez Castrejon AM; DuBois RM; Tripp RA
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672319
[TBL] [Abstract][Full Text] [Related]
5. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein.
Tripp RA; Jones LP; Haynes LM; Zheng H; Murphy PM; Anderson LJ
Nat Immunol; 2001 Aug; 2(8):732-8. PubMed ID: 11477410
[TBL] [Abstract][Full Text] [Related]
6. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis.
Amanatidou V; Sourvinos G; Apostolakis S; Tsilimigaki A; Spandidos DA
Pediatr Infect Dis J; 2006 May; 25(5):410-4. PubMed ID: 16645504
[TBL] [Abstract][Full Text] [Related]
7. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
[TBL] [Abstract][Full Text] [Related]
8. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses.
Chirkova T; Boyoglu-Barnum S; Gaston KA; Malik FM; Trau SP; Oomens AG; Anderson LJ
J Virol; 2013 Dec; 87(24):13466-79. PubMed ID: 24089561
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.
Choi Y; Mason CS; Jones LP; Crabtree J; Jorquera PA; Tripp RA
Viral Immunol; 2012 Jun; 25(3):193-203. PubMed ID: 22551066
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
[TBL] [Abstract][Full Text] [Related]
13. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
14. Role of complement in neutralization of respiratory syncytial virus.
Yoder SM; Zhu Y; Ikizler MR; Wright PF
J Med Virol; 2004 Apr; 72(4):688-94. PubMed ID: 14981775
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
16. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus: reverse genetics and vaccine strategies.
Collins PL; Murphy BR
Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
[No Abstract] [Full Text] [Related]
18. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes.
Hancock GE; Tebbey PW; Scheuer CA; Pryharski KS; Heers KM; LaPierre NA
J Med Virol; 2003 Jun; 70(2):301-8. PubMed ID: 12696122
[TBL] [Abstract][Full Text] [Related]
19. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
[TBL] [Abstract][Full Text] [Related]
20. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
